All News

Wendy St Peter, PharmD, explains how the new cardio-kidney-metabolic (CKM) syndrome guideline supports pharmacist-led medication management, staging tools, and deprescribing.

Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, discusses the New England Institute for Ambulatory Care Pharmacy (NEIAP) Annual Forum and previews key topics of discussion.

As cannabis evolves, pharmacists must recognize emerging risks from high-potency products, drug interactions, and use-related syndromes to improve patient safety.

Laura Gillespie, PharmD, discusses how her patient-first approach has guided her research collaboration efforts and led to measurable reductions in C difficile infection rates at her institution.

Deanna Horner, PharmD, BCPS, discusses how payers, employers, and health plans can approach GLP-1 coverage by balancing patient access, affordability, clinical value, and long-term cost considerations.

Jennifer Goldman, PharmD, RPh, CDCES, BC-ADM, FCCP, shares the history and mission of NEIAP and explains how the organization provides practical education and networking opportunities.

In addition to explaining how NEIAP has evolved over time, Katelyn O'Brien, PharmD, BCPS, CDCES, BC-ADM, previews key topics at the upcoming September meeting.

This study validates the need for universal HBV therapy for hepatitis B infections among people coinfected with HIV.

The FDA expanded Casgevy’s indication to include children 2 years and older with sickle cell disease with recurrent VOCs or transfusion-dependent β-thalassemia, making it the first gene therapy approved for patients as young as 2 years with SCD.

The systems connecting care are proving just as important as the treatments themselves.

AZA Allsop, MD, PhD, outlines what REMS-style safety monitoring could look like for psychedelic therapies and why top institutions are investing heavily.

In modernizing sunscreen options, the FDA has added the first new organic active ingredient, bemotrizinol, to the OTC sunscreen monograph.

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on how health systems can evaluate suzetrigine for acute pain pathways while balancing evidence, access, formulary sustainability, and pharmacist-led stewardship.

The NIH’s expanded All of Us data set links genomic, clinical, environmental, and wearable data from a diverse population to advance precision medicine and pharmacogenomic research.

Because influenza outbreaks follow a humidity‑temperature curve, climate change may shift flu epidemics and reshape risk from tropics to temperate regions.

Pharmacists who understand both the clinical and the contractual dimensions of these policies are positioned to translate between the payer's cost logic and the provider's patient safety argument.

A study found worsening chronic kidney disease (CKD) severity was independently associated with increased mortality risk and exponentially higher rates of kidney replacement therapy initiation following ICU admission.

A systematic review of 23 randomized trials suggests melatonin may modestly reduce musculoskeletal pain and improve sleep, although pharmacists should emphasize uncertain dosing, supplement quality, and the need to use it only as an adjunct to individualized pain care.

Candel Therapeutics has launched the global phase 3 AURORA trial to evaluate investigational viral immunotherapy in patients with advanced non–small cell lung cancer.

Messenger RNA vaccines were effective against any documented SARS-CoV-2 infection, against hospitalization, and against mortality within 14 to 42 days of vaccination.

Guests Adrian Wong, PharmD, MPH, BCCCP; and Cayley Krkljes, PharmD, BCPS, about a systematic review of phenobarbital and primidone drug-drug interactions, highlighting clinically significant risks when used with other therapies.

The POSEIDON clinical trial shows that high-sensitivity C-reactive protein levels remain elevated in approximately 2 in 5 patients with CVD, pointing to a gap in residual inflammatory risk management.

COVID-19 boosters can also neutralize certain bat and pangolin coronaviruses, while immune "imprinting" from a person's first viral exposure limits how well that protection adapts to newer variants.

Only 3 uncontrolled pilot studies with a combined sample size of 30 participants have been reported for BPC-157.

Pharmacy Times interviews Tanya J. Uritsky, PharmD, BCPP, FPPCP, FASHP, on why effective opioid stewardship in acute pain care must extend beyond prescription reduction to include multimodal analgesia, patient-centered outcomes, and standardized health-system pathways.

A randomized clinical trial found that both family-based therapy and individual psychoeducational motivational therapy improved symptoms of avoidant/restrictive food intake disorder.

Recent research and drug developments are reshaping clinical practice.

Yale's AZA Allsop, MD, PhD, on psychedelics as medicine vs wellness tools, and why naturalistic research settings matter for the field.